Drug intelligence / Profile preview

uPRIT

Development stage: Preclinical
Lead developer: Monopar Therapeutics
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

uPRIT is a radiopharmaceutical candidate developed by Monopar Therapeutics and NorthStar Medical Radioisotopes as part of the uPRIT platform, designed for targeted imaging or therapy, potentially in severe COVID-19 patients. It leverages NorthStar's expertise in radioisotope production combined with Monopar's targeting technologies to deliver radiation to diseased tissues selectively. The candidate was selected for preclinical studies, but no further details on mechanism, indications beyond initial COVID-19 consideration, or clinical advancement are publicly available.[8]

Targets

PLAUR (Urokinase plasminogen activator receptor)

Beyond the preview

Go deeper on uPRIT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on uPRIT.

Explore the full profile